Navigation Links
Stemedica International Announces Joint Venture with AnC Bio Group
Date:10/5/2010

SAN DIEGO, Oct. 5 /PRNewswire/ -- Stemedica International, S.A., ("Stemedica"), a wholly owned subsidiary of Stemedica Cell Technologies, Inc., announced the signing of an agreement to form a joint venture with AnC Bio, a global manufacturer of stem cell-based products.  The new venture, StemedicaAnC, will manufacture stem cells developed by Stemedica for the treatment of ischemic stroke and other degenerative disorders.  The initial manufacturing capacity of this alliance will produce enough products to meet the Company's five-year revenue projections, with an expansion capacity to manufacture multiple stem cell products to meet the anticipated long-term growth of the international market for stem cells.  

AnC's biomanufacturing facility was built at an estimated cost of 120 million dollars over a five year period.  "The synergy between Stemedica's technology and AnC's technically advanced manufacturing facility positions StemedicaAnC as the global leader in stem cell production," said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer.  "The facility will provide StemedicaAnC with the capacity to manufacture its multiple allogeneic stem cell products to meet international safety and quality standards established by the United States FDA, Swissmedic, the European regulatory agency and Korea's FDA."

"We are pleased to be working with Stemedica to accelerate the advancement of stem cell therapy," said Alex Choi, Chairman and Chief Executive Officer of the AnC Bio Group.  "This joint venture will provide stem cell products to institutions around the world that are conducting clinical trials and stem cell research."

"We have invested significant time and effort in our search for a best-in-class stem cell manufacturing facility to accommodate our technology," said Roger J. Howe, PhD, Executive Chairman of Stemedica.  "AnC Bio provides an excellent fit for our international business development strategy."

"This is an exciting time for both companies," said Ike W. Lee, PhD, President and Chief Technology Officer of AnC Bio.  "Stemedica's advanced technology and operating systems will be a significant addition to AnC Bio's manufacturing facility.  I am looking forward to working with their team of scientists and engineers."

The joint venture will be overseen by a Board of Directors representing both Stemedica and AnC Bio.  Planning for operations is expected to begin by year end.

About Stemedica Cell Technologies, Inc.Stemedica Cell Technologies, Inc. (www.stemedica.com) is a specialty biopharmaceutical company that develops and manufactures best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials.  The company is currently developing regulatory pathways for neurology, cardiology, ophthalmology, wound care and dermatology. Stemedica is headquartered in San Diego, California.  For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan@stemedica.com

About AnC Bio GroupAnC Bio Group is a Korean Corporation with three operating divisions: the cell therapy division which includes a state-of-the-art cell culture cGMP facility; the artificial organs division that designs, manufactures and distributes artificial human organs such as kidney dialysis and artificial combined heart and lung machines; and the vaccine division that develops, manufactures and distributes various kinds of cell culture-based vaccines including influenza, avian, Alzheimer's and anthrax. For more information regarding AnC Bio, please visit www.ancbio.com. Media contact:Dave McGuiganStemedica Cell Technologies Inc.+18586580910dmcguigan@stemedica.comhttp://www.stemedica.com
'/>"/>

SOURCE Stemedica International, S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
2. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
3. Stemedica Requests Pre-IND Meeting With FDA
4. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
5. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
6. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
7. International Robotic Urology Symposium 2011
8. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
9. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
10. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
11. Webmedx and NLP International Team to Bring Natural Language Processing Software to Medical Transcription
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):